Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

96.97 -2.02 (-2.04%)
Official Closing Price Updated: 7:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,772,715
Open 97.15
Bid (Size) 97.20 (1)
Ask (Size) 100.00 (1)
Prev. Close 98.99
Today's Range 96.90 - 97.48
52wk Range 79.98 - 105.61
Shares Outstanding N/A
Dividend Yield 3.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
(NVS) - Analyzing Novartis's Short Interest
Via Benzinga
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment... 
Via SBWire

Performance

YTD
+5.16%
+5.16%
1 Month
+3.77%
+3.77%
3 Month
-1.14%
-1.14%
6 Month
-4.36%
-4.36%
1 Year
+6.61%
+6.61%

More News

Read More
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Via SBWire
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Via Benzinga
Exposures Product Safety
3 Healthcare Stocks to Pick Up Before the Year-End Rally
Via InvestorPlace
How Is The Market Feeling About Novartis?
Via Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off
Via Benzinga
Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028
Via SBWire
Exposures Product Safety
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
Via Investor's Business Daily
2 overlooked stocks that crushed earnings but traded lower
Via MarketBeat
Exposures Product Safety
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Via Talk Markets
Diversifying Your Portfolio With Plant-Based Options
Via Talk Markets
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
Via The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Via FinancialNewsMedia
Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug
Via Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
Via The Motley Fool
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via FinancialNewsMedia
Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
Via Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
Via Benzinga
Exposures Product Safety
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
2 Green Flags and 1 Red Flag for Novartis Stock
Via The Motley Fool
7 Undervalued Stocks to Buy Before Everyone Else
Via InvestorPlace
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.